Novartis: EU approval for product label on Tasigna.
(CercleFinance.com) - Novartis said on Tuesday that it has received EU approval for inclusion of treatment-free remission (TFR) data in the product label of its blood cancer drug Tasigna.
Treatment-free remission is the ability to maintain molecular response after stopping tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in its chronic phase, the Swiss company said.
The approval was based on the findings of two 48-week trials, which showed that over 50% of patients with the disease were able to maintain TFR after stopping Tasigna after switching from Glivec.
Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) is a type of cancer in which the body produces cancerous white blood cells.
Separately, Novartis yesterday announced a clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer.
Novartis also unveiled a "ground-breaking collaboration" with IBM Watson's artificial intelligence on outcomes-based care in advanced breast cancer.
Last Sunday Novartis said a study on Tafinlar and Mekinist demonstrated durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Treatment-free remission is the ability to maintain molecular response after stopping tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in its chronic phase, the Swiss company said.
The approval was based on the findings of two 48-week trials, which showed that over 50% of patients with the disease were able to maintain TFR after stopping Tasigna after switching from Glivec.
Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) is a type of cancer in which the body produces cancerous white blood cells.
Separately, Novartis yesterday announced a clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer.
Novartis also unveiled a "ground-breaking collaboration" with IBM Watson's artificial intelligence on outcomes-based care in advanced breast cancer.
Last Sunday Novartis said a study on Tafinlar and Mekinist demonstrated durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma.
Copyright (c) 2017 CercleFinance.com. All rights reserved.